Clinical Trials Logo

Heroin Abuse clinical trials

View clinical trials related to Heroin Abuse.

Filter by:
  • None
  • Page 1

NCT ID: NCT05074524 Completed - Opioid-use Disorder Clinical Trials

Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings

Start date: October 6, 2021
Phase: N/A
Study type: Interventional

The purpose of this research study is to test the effect of repetitive transcranial magnetic stimulation (rTMS) on opioid cravings among adult patients with Opioid Use Disorder.

NCT ID: NCT04567784 Recruiting - Clinical trials for Substance-Related Disorders

Neuroimaging and CBD for Opiod Use Disorder

Start date: November 12, 2020
Phase: Phase 2
Study type: Interventional

The investigators propose an imaging study to investigate the neurobiological effects of CBD (vs placebo) in participants with opioid use disorder who are maintained on methadone. The purpose of the study is to determine the neural circuits and transmitters associated with the effects of CBD on to reduce craving and anxiety. The neuroimaging will be conducted in participants immediately following their first administration of CBD (800mg or placebo) and one week after the last administration (3 daily doses). This CBD administration protocol was shown in previous studies by the investigators to reduce craving and anxiety in abstinent heroin users.

NCT ID: NCT03971097 Completed - Clinical trials for Alcohol Use Disorder

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, & Maguen, 2018) and the Substance Abuse Self-Stigma Scale (SASSS) (Luoma et al., 2013). Data will be collected from two groups of participants receiving counseling at the short-term rehabilitation facility located at University of Pittsburgh Medical Center's (UPMC). Individuals who agree to participate in the study will be randomly assigned to either the experimental group (EG) or the control group (CG). Data collected will include pre-test SFDPS and SASSS scores for the EG and the CG (collected within 24-hours of admission), and post-test SFDPS and SASSS scores for the EG and CG (collected after 14 days). ANCOVA will be used to analyze the pre-test and post-test data recorded from participants' scores.

NCT ID: NCT00318760 Completed - Cocaine Abuse Clinical Trials

Effect of Clonidine on Responses to Imagery Scripts

Start date: June 14, 2005
Phase: Phase 1
Study type: Interventional

Background: - Research has shown that clonidine, a drug originally prescribed to treat high blood pressure and some symptoms of opioid withdrawal, can help block stress-induced relapse to heroin and cocaine seeking in rats. However, it does not seem to block cue-induced relapse in rats. Researchers are interested in studying whether clonidine shows the same pattern of effects on stress- and cue-induced cravings for heroin or cocaine in humans. Objectives: - To compare the ability of clonidine to reduce stress- and cue-induced cocaine and heroin craving in drug abusers. Eligibility: - Individuals between 18 and 55 years of age who are current cocaine or heroin users. Design: - This study will consist of two visits: a screening visit to determine eligibility and an experimental/script session. - Before the script session, participants will provide urine and breath samples for testing. Participants will complete questionnaires to measure their current drug craving and days since last use of cocaine or heroin. - At the start of the script session, participants will receive a dose of clonidine or placebo as directed by the study researchers. Three hours after dosing, participants will be read four scripts (two neutral, one stress-inducing, and one drug-cue-related) with breaks in between each script. After each script, participants will respond to questions about levels of stress and craving. - Participants will provide saliva samples immediately before and during the script readings, and will also be measured for skin response to the scripts.